Xenetic Biosciences, Inc. (XBIO)

Expanding the Potential of CAR T Cell Therapy

Xenetic Biosciences is a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens.

More About Us

Combating Disease Through Innovative Therapies

Product Pipeline

Platform

Personalized CAR T platform targeting cancers with a patient- and tumor-specific approach.

XCART Platform

Transformative Technologies

Our proprietary and patented technologies are being utilized to create life-changing therapies.

Our Novel Technologies

Latest News

Jul 28, 2021

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market

Jul 26, 2021

Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market

Stock Information • View Detailed Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.

Price

Change

Volume

Day Range

52 Week Range

Investor Presentation

View Investor Presentation

Get Email Alerts

Stay informed about our latest news and updates